| scholarly article | Q13442814 |
| P50 | author | Margaret Hilda Harper | Q21536453 |
| Alan M. Peaceman | Q37387687 | ||
| Michael W. Varner | Q37387705 | ||
| Yoram Sorokin | Q61835670 | ||
| Catherine Y Spong | Q61845595 | ||
| Leslie Myatt | Q66941734 | ||
| George Saade | Q87949010 | ||
| Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network | Q87949515 | ||
| Jay Iams | Q92062360 | ||
| Susan M. Ramin | Q110252023 | ||
| Brian M. Mercer | Q110265628 | ||
| John C Hauth | Q110266322 | ||
| Jorge E Tolosa | Q114736434 | ||
| Anthony Sciscione | Q114736435 | ||
| P2093 | author name string | James M Roberts | |
| Rebecca G Clifton | |||
| John M Thorp | |||
| Marshall W Carpenter | |||
| Garland D Anderson | |||
| P2860 | cites work | Immunohistochemical demonstration of pregnancy-associated plasma protein A (PAPP-A) in the syncytiotrophoblast of the normal placenta at different gestational ages | Q28259331 |
| Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) | Q28275001 | ||
| Vitamins C and E to prevent complications of pregnancy-associated hypertension | Q33389072 | ||
| Prediction of preeclampsia. | Q33548009 | ||
| Role of the IGF system in trophoblast invasion and pre-eclampsia | Q33848129 | ||
| The familial factor in toxemia of pregnancy | Q34238688 | ||
| Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies | Q34470990 | ||
| Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome | Q34610789 | ||
| First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 | ||
| Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort | Q34769574 | ||
| The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. | Q35135723 | ||
| The prediction of adverse maternal outcomes in preeclampsia | Q35928615 | ||
| The two stage model of preeclampsia: variations on the theme | Q37187589 | ||
| Human placental trophoblasts secrete a disintegrin metalloproteinase very similar to the insulin-like growth factor binding protein-3 protease in human pregnancy serum | Q41716618 | ||
| Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. | Q44806764 | ||
| Longitudinal study of platelet indices during normal pregnancy | Q45220245 | ||
| Preeclampsia: increased expression of soluble ADAM 12. | Q46343091 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Mean platelet volume in patients with prehypertension and hypertension | Q56780658 | ||
| Maternal serum placental protein 13 at 11â 13 weeks of gestation in preeclampsia | Q61847857 | ||
| Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation | Q61853217 | ||
| Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia | Q61865449 | ||
| Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial | Q72285628 | ||
| Platelet indices during normal pregnancy and pre-eclampsia | Q73009041 | ||
| Pulse pressure and risk of preeclampsia: a prospective study | Q73686283 | ||
| First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 | ||
| Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia | Q79829262 | ||
| ADAM12s in maternal serum as a potential marker of pre-eclampsia | Q80673251 | ||
| Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia | Q81920292 | ||
| Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks | Q82674081 | ||
| Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study | Q82737458 | ||
| Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease | Q84133100 | ||
| Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes | Q84719535 | ||
| Prediction model for hypertension in pregnancy in nulliparous women using information obtained at the first antenatal visit | Q84887936 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| P304 | page(s) | 1234-1242 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Obstetrics and Gynecology | Q7075543 |
| P1476 | title | First-trimester prediction of preeclampsia in nulliparous women at low risk | |
| P478 | volume | 119 |
| Q35287430 | A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). |
| Q37289388 | A label-free selected reaction monitoring workflow identifies a subset of pregnancy specific glycoproteins as potential predictive markers of early-onset pre-eclampsia |
| Q59612693 | A novel method for interrogating receiver operating characteristic curves for assessing prognostic tests |
| Q55036332 | Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. |
| Q54406971 | Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. |
| Q38370968 | Angiogenic biomarkers in pregnancy: defining maternal and fetal health |
| Q58035948 | Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study |
| Q27692060 | Angiogenic factors in diagnosis, management, and research in preeclampsia |
| Q28607419 | Antenatal blood pressure for prediction of pre-eclampsia, preterm birth, and small for gestational age babies: development and validation in two general population cohorts |
| Q58715759 | Anthropoid primate-specific retroviral element THE1B controls expression of CRH in placenta and alters gestation length |
| Q46301199 | Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? |
| Q54376760 | Authors' reply: Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. |
| Q38597467 | Availability of COLLECT, a database for pregnancy and placental research studies worldwide |
| Q46306526 | Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks? |
| Q33923716 | Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? |
| Q57316852 | Can prenatal screening reduce the adverse obstetric outcomes related to abnormal placentation? |
| Q91271724 | Cell- and size-specific analysis of placental extracellular vesicles in maternal plasma and pre-eclampsia |
| Q37711864 | Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia |
| Q38209381 | Clinical applications of biomarkers in preeclampsia |
| Q35747044 | Combination of PAPPA, fhCGβ, AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia |
| Q30820019 | Community health workers' knowledge and practice in relation to pre-eclampsia in Ogun State, Nigeria: an essential bridge to maternal survival. |
| Q35849525 | Descriptive epidemiology of chronic hypertension, gestational hypertension, and preeclampsia in New York State, 1995-2004 |
| Q34289412 | Development and validation of a risk factor scoring system for first-trimester prediction of preeclampsia |
| Q33579089 | Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). |
| Q26781355 | Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis |
| Q48609992 | Endometrial vascularity is lower in pregnancies with pregnancy-induced hypertension or small-for-gestational-age fetus in live birth after in-vitro fertilization. |
| Q92980466 | Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia |
| Q37404418 | Evidence of sexual dimorphism in the placental function with severe preeclampsia. |
| Q38954935 | First trimester screening for pre-eclampsia |
| Q89082273 | First-Trimester Uterine Artery Pulsatility Index and Maternal Serum PAPP-A and PlGF in Prediction of Preeclampsia in Primigravida |
| Q48008304 | First-trimester hyperglycosylated human chorionic gonadotropin and development of hypertension |
| Q38432783 | First-trimester screening for preeclampsia: impact of maternal parity on modeling and screening effectiveness |
| Q54439388 | First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. |
| Q36742604 | Follistatin-like 3 across gestation in preeclampsia and uncomplicated pregnancies among lean and obese women |
| Q28081459 | Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia |
| Q36408977 | Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia |
| Q38848542 | Gestational diabetes mellitus and first trimester pregnancy-associated plasma protein A: A case-control study in a Chinese population |
| Q33406987 | Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population |
| Q27009441 | If we know so much about preeclampsia, why haven't we cured the disease? |
| Q91564952 | Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: a nested case-control study |
| Q45002550 | Increased levels of copeptin before clinical diagnosis of preelcampsia |
| Q40785328 | Intrapartum mean platelet volume is not a useful predictor of new-onset delayed postpartum pre-eclampsia |
| Q33826353 | Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy |
| Q34876147 | Mid-trimester maternal ADAM12 levels differ according to fetal gender in pregnancies complicated by preeclampsia |
| Q55249178 | Mining DNA methylation alterations towards a classification of placental pathologies. |
| Q37348561 | Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia |
| Q26861380 | Placental Protein 13 (PP13) - A Placental Immunoregulatory Galectin Protecting Pregnancy |
| Q55689583 | Placental protein 13: An important biological protein in preeclampsia. |
| Q38219228 | Pre-eclampsia: an update |
| Q36343649 | Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters |
| Q46304043 | Prediction of preeclampsia in primigravida in late first trimester using serum placental growth factor alone and by combination model |
| Q38207099 | Predictive biomarkers of pre-eclampsia and effectiveness of preventative interventions for the disease |
| Q36140001 | Predictor characteristics necessary for building a clinically useful risk prediction model: a simulation study |
| Q35358822 | Preeclampsia and associated factors among pregnant women attending antenatal care in Dessie referral hospital, Northeast Ethiopia: a hospital-based study |
| Q60913447 | Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction |
| Q38585309 | Preeclampsia: Syndrome or Disease? |
| Q33715526 | Pregnancy, parturition and preeclampsia in women of African ancestry |
| Q35016027 | Prevention and management of severe pre-eclampsia/eclampsia in Afghanistan |
| Q45810222 | Relationship between placental grade and mean platelet volume |
| Q89558753 | Resident physicians' and Midwives' Knowledge of Preeclampsia and Eclampsia Reflected in Their Practice at a Clinical Hospital in Southern Romania |
| Q50638104 | Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. |
| Q41545353 | Serial determinations of asymmetric dimethylarginine and homocysteine during pregnancy to predict pre-eclampsia: a longitudinal study |
| Q90447011 | Significance of platelet indices as severity marker in nonthrombocytopenic preeclampsia cases |
| Q44652577 | Statistical regression model of standard and new laboratory markers and its usefulness in prediction of preeclampsia |
| Q36014095 | The Effect of High Dose Folic Acid throughout Pregnancy on Homocysteine (Hcy) Concentration and Pre-Eclampsia: A Randomized Clinical Trial |
| Q37622169 | The Level of Serum and Urinary Nephrin in Normal Pregnancy and Pregnancy with Subsequent Preeclampsia |
| Q37489857 | The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes |
| Q34629295 | The importance of early life in childhood obesity and related diseases: a report from the 2014 Gravida Strategic Summit |
| Q37234812 | The loss of sustained Ca(2+) signaling underlies suppressed endothelial nitric oxide production in preeclamptic pregnancies: implications for new therapy |
| Q47109831 | The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes. |
| Q36253829 | The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population |
| Q90011558 | Vascular Endothelial Growth Factor Delivery to Placental Basal Plate Promotes Uterine Artery Remodeling in the Primate |
Search more.